Insight Molecular Diagnostics
IMDX | NASDAQ
$1.86
-$0.28 (-13.08%)
At close: Nov 16, 2026, 4:00 PM ET
$1.53
-$0.33 (-17.74%)
After-hours:
Nov 16, 2026, 7:55 PM ET
-13.08%
(1D)No price chart data available for 1D timeframe.
Rating
32.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #720/1021 (Top 71%)
Key Statistics
Market Data
Market Cap $68.36M
1D Range
1.85 2.11
52W Range
1.85 7.50
Valuation (TTM)
PE -1.22
PB -3.21
EV/EBITDA -1.14
Valuation (NTM)
Forward PE N/A
Forward PEG 0.07
Price Target $12.00
Cash Flow
FCF Yield -45.2%
SBC Adj. FCF Yield -48.9%
SBC Impact -8.2%
Margins
Gross Margin 11.2%
Operating Margin -2558.7%
FCF Margin -1848.8%
Growth (CAGR)
Revenue 3Y | 5Y 14.9% |
-16.9%
Dil EPS 3Y | 5Y 44.4% |
48.1%
FCF 3Y | 5Y -28.8% |
14.3%
Returns
ROA -167.6%
ROE 271.8%
ROIC -204.8%
Financial Health
Net Cash
$17.76M
Current Ratio 2.00
Interest Coverage -436.03
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identificat...
Sector Healthcare
Industry Medical - Diagnostics & Research
Employees 57
IPO Date Dec 30, 2015
Website imdxinc.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 16, 2026
EPS
-$0.19
Beat +19.49%
YoY:
+44.12% REV
$559K
Beat +128.84%
YoY:
+115.00%Next Earnings
Apr 1, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$12.00
Upside
+545.16%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove IMDX